NCT04527354 - Pilot Study to Assess Efficacy and Safety of Treamid in the Rehabilitation of Patients After COVID-19 Pneumonia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 1, 2020

Primary Completion Date

February 10, 2021

Study Completion Date

February 10, 2021

Conditions

SARS-CoV-2 InfectionFibrosis Lung

Interventions

DRUG

Treamid

Participants will receive Treamid 50 mg once a day during 4 weeks

DRUG

Placebo

Participants will receive Placebo once a day during 4 weeks

Trial Locations (8)

105094

"Federal State Budgetary Institution N.N. Burdenko Military Clinical Hospital", Moscow

119435

SBEI HPE The First Moscow State Medical University n.a. Sechenov of Ministry of Health of Russian Federation, University Hospital #2, Department of Development of New Medicines, Moscow

121552

"Moscow State Medical-Dentist University n.a. A.I. Evdokimov on basis of SMHI City Hospital № 62, branch 5", Moscow

150003

"State autonomous healthcare institution of Yaroslavl Region Сlinical hospital for emergency medical care n. a. N.V. Solovyov", Yaroslavl

185019

"State Budgetary Health Institution Republican Hospital named V.A.Baranov", Petrozavodsk

194354

"LLC Medical Center Reavita Med St. Petersburg", Saint Petersburg

344068

"Federal State Budgetary Educational Institution of Higher Education Rostov State Medical University", Rostov-on-Don

650002

"Federal State-Funded Research Institution Research Institute of Complex Cardiovascular Diseases", Kemerovo

All Listed Sponsors

lead

PHARMENTERPRISES LLC

INDUSTRY